FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2062098889> ?p ?o ?g. }

• W2062098889 endingPage "18" @default.
• W2062098889 startingPage "12" @default.
• W2062098889 abstract "Neovascularization in the eye is a major cause of irreversible vision loss. The present study was undertaken to determine mechanisms through which pazopanib, a drug that targets multiple receptor tyrosine kinases such as VEGF receptors, inhibits angiogenesis and experimental choroidal neovascularization (CNV). Pazopanib inhibited VEGF expression by retinal pigment epithelium (RPE) cells and choroidal endothelial cells (CEC), decreased VEGF-induced cellular migration in a dose-dependent manner and suppressed extracellular signal-regulated kinase (ERK)-1/-2 phosphorylation. To assess the impact of pazopanib in vivo, CNV was induced in rats by rupturing the Bruch's membrane by laser coagulation. These experiments demonstrated that twice-daily topical eye drop treatment significantly (P<0.001) decreased leakage from photocoagulated lesions by 89.5%. Furthermore, the thickness of the developed CNV lesions was significantly inhibited by 71.7% (P<0.001) in pazopanib-treated eyes, and immunoreactivity of VEGF was lower than in control eyes. Our data suggest that pazopanib is a promising inhibitor of angiogenesis leading to an effective inhibition of CNV development in vivo. This activity can be largely ascribed to the down-regulation of VEGF release in the retina as well as to impaired VEGF-induced signaling and chemotaxis. Using a convenient topical dosing regimen, pazopanib may prove useful for treating a variety of ocular neovascular diseases such as neovascular age-related macular degeneration." @default.
• W2062098889 created "2016-06-24" @default.
• W2062098889 creator A5002720147 @default.
• W2062098889 creator A5011319353 @default.
• W2062098889 creator A5016341977 @default.
• W2062098889 creator A5018272749 @default.
• W2062098889 creator A5031023662 @default.
• W2062098889 creator A5076681274 @default.
• W2062098889 creator A5086910361 @default.
• W2062098889 creator A5088583341 @default.
• W2062098889 creator A5089557418 @default.
• W2062098889 date "2011-09-01" @default.
• W2062098889 modified "2023-09-25" @default.
• W2062098889 title "Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats" @default.
• W2062098889 cites W1554075898 @default.
• W2062098889 cites W1974228208 @default.
• W2062098889 cites W1975926216 @default.
• W2062098889 cites W1981427921 @default.
• W2062098889 cites W1987454669 @default.
• W2062098889 cites W1998832530 @default.
• W2062098889 cites W1999414884 @default.
• W2062098889 cites W1999961827 @default.
• W2062098889 cites W2000292756 @default.
• W2062098889 cites W2003598961 @default.
• W2062098889 cites W2003797682 @default.
• W2062098889 cites W2007897471 @default.
• W2062098889 cites W2009158237 @default.
• W2062098889 cites W2047470479 @default.
• W2062098889 cites W2051268134 @default.
• W2062098889 cites W2051842051 @default.
• W2062098889 cites W2057697484 @default.
• W2062098889 cites W2066639629 @default.
• W2062098889 cites W2069417222 @default.
• W2062098889 cites W2078317173 @default.
• W2062098889 cites W2082495294 @default.
• W2062098889 cites W2085712747 @default.
• W2062098889 cites W2099022883 @default.
• W2062098889 cites W2112940666 @default.
• W2062098889 cites W2124415048 @default.
• W2062098889 cites W2133784172 @default.
• W2062098889 cites W2134382856 @default.
• W2062098889 cites W4253705647 @default.
• W2062098889 doi "https://doi.org/10.1016/j.ejphar.2011.05.016" @default.
• W2062098889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21620822" @default.
• W2062098889 hasPublicationYear "2011" @default.
• W2062098889 type Work @default.
• W2062098889 sameAs 2062098889 @default.
• W2062098889 citedByCount "38" @default.
• W2062098889 countsByYear W20620988892012 @default.
• W2062098889 countsByYear W20620988892013 @default.
• W2062098889 countsByYear W20620988892014 @default.
• W2062098889 countsByYear W20620988892015 @default.
• W2062098889 countsByYear W20620988892017 @default.
• W2062098889 countsByYear W20620988892018 @default.
• W2062098889 countsByYear W20620988892019 @default.
• W2062098889 countsByYear W20620988892020 @default.
• W2062098889 countsByYear W20620988892021 @default.
• W2062098889 countsByYear W20620988892022 @default.
• W2062098889 countsByYear W20620988892023 @default.
• W2062098889 crossrefType "journal-article" @default.
• W2062098889 hasAuthorship W2062098889A5002720147 @default.
• W2062098889 hasAuthorship W2062098889A5011319353 @default.
• W2062098889 hasAuthorship W2062098889A5016341977 @default.
• W2062098889 hasAuthorship W2062098889A5018272749 @default.
• W2062098889 hasAuthorship W2062098889A5031023662 @default.
• W2062098889 hasAuthorship W2062098889A5076681274 @default.
• W2062098889 hasAuthorship W2062098889A5086910361 @default.
• W2062098889 hasAuthorship W2062098889A5088583341 @default.
• W2062098889 hasAuthorship W2062098889A5089557418 @default.
• W2062098889 hasConcept C101544691 @default.
• W2062098889 hasConcept C118487528 @default.
• W2062098889 hasConcept C121608353 @default.
• W2062098889 hasConcept C126322002 @default.
• W2062098889 hasConcept C146285616 @default.
• W2062098889 hasConcept C14858245 @default.
• W2062098889 hasConcept C150903083 @default.
• W2062098889 hasConcept C167734588 @default.
• W2062098889 hasConcept C170493617 @default.
• W2062098889 hasConcept C184235292 @default.
• W2062098889 hasConcept C207001950 @default.
• W2062098889 hasConcept C2776403814 @default.
• W2062098889 hasConcept C2777025900 @default.
• W2062098889 hasConcept C2778271429 @default.
• W2062098889 hasConcept C2778439243 @default.
• W2062098889 hasConcept C2778820342 @default.
• W2062098889 hasConcept C2779490328 @default.
• W2062098889 hasConcept C2780394083 @default.
• W2062098889 hasConcept C2781359195 @default.
• W2062098889 hasConcept C42362537 @default.
• W2062098889 hasConcept C502942594 @default.
• W2062098889 hasConcept C57074206 @default.
• W2062098889 hasConcept C71924100 @default.
• W2062098889 hasConcept C86803240 @default.
• W2062098889 hasConcept C95444343 @default.
• W2062098889 hasConcept C98274493 @default.
• W2062098889 hasConceptScore W2062098889C101544691 @default.
• W2062098889 hasConceptScore W2062098889C118487528 @default.
• W2062098889 hasConceptScore W2062098889C121608353 @default.

• next